Edition:
United Kingdom

People: Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

13.42USD
9:00pm BST
Change (% chg)

$0.08 (+0.60%)
Prev Close
$13.34
Open
$13.62
Day's High
$13.86
Day's Low
$13.29
Volume
465,114
Avg. Vol
507,939
52-wk High
$49.87
52-wk Low
$11.50

Mahaffy, Patrick 

Mr. Patrick J. Mahaffy is President, Chief Executive Officer, Co-Founder, Director of the Company. Mr. Mahaffy is one of our co-founders and has served as our President and Chief Executive Officer and a member of our board of directors since our inception. Previously, Mr. Mahaffy served as President and Chief Executive Officer and as a member of the board of directors at Pharmion Corporation, which he founded in 2000 and sold to Celgene Corporation in 2008. From 1992 through 1998, Mr. Mahaffy was President and Chief Executive Officer of NeXagen, Inc. and its successor, NeXstar Pharmaceuticals, Inc., a biopharmaceutical company. Prior to that, Mr. Mahaffy was a Vice President at the private equity firm E.M. Warburg Pincus and Co. Mr. Mahaffy also serves on the boards of directors of Flexion Therapeutics, Inc. (NASDAQ: FLXN) and Orexigen Therapeutics, Inc. (NASDAQ: OREX). He is also a trustee of Lewis and Clark College. Mr. Mahaffy has a B.A. in international affairs from Lewis and Clark College and a M.A. in international affairs from Columbia University.

Basic Compensation

Total Annual Compensation, USD 1,078,510
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 5,188,950
Fiscal Year Total, USD 6,267,460

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ginger Graham

357,479

Patrick Mahaffy

6,267,460

Gillian Ivers-Read

1,764,020

Daniel Muehl

1,509,580

Paul Gross

--

Ann Bozeman

--
As Of  31 Dec 2018